An FDA advisory panel just voted to add two more compounds to the peptide compounding list, and if you have never heard that phrase before, it is about to matter to you. Six peptides cleared review in two days. The agency’s own scientists recommended rejecting every single one of them.
Start with the plumbing, because almost nobody explains this part and it is the part that decides everything.
Compounding pharmacies are specialized pharmacies that prepare medications individually rather than manufacturing them at scale. The peptide compounding list, known formally as the bulk 503A list, is the roster of substances those pharmacies are allowed to prepare. Once a substance lands on that roster, a compounding pharmacy can make it without further agency review.
Here is the detail that should stop you. Officials stated plainly during the hearings that once a compound is on the peptide compounding list, the FDA cannot require the people making it to submit safety or efficacy data. Not “will not.” Cannot.
So the peptide compounding list is not an approval. It is not a seal of quality. It is a permission structure. It says a thing may be made. It says nothing whatsoever about whether the batch in front of you was made well.
Peptides themselves are short chains of amino acids that signal cells to carry out tasks, things like reducing inflammation or triggering repair. That biology is real and it was never the argument. The argument is about oversight, and the peptide compounding list is where that argument gets settled.
Across two days, a federal advisory committee reviewed a batch of peptides for the compounding list and cleared six of them.
On the first day the panel recommended four: BPC-157, KPV, MOTS-c and TB-500. On the second day it took up three more. Epitalon was backed seven to four, marketed for insomnia and longevity. Semax was backed eight to five, promoted for migraine and neurological conditions including stroke and facial nerve pain. Emideltide was rejected six to seven.
Epitalon drew the most attention, and for good reason. Some laboratory work suggests it may lengthen telomeres, the protective caps on your chromosomes that shorten as you age. That is exactly the kind of finding that gets a compound onto a peptide compounding list conversation in the first place. FDA scientists cautioned that long-term exposure could raise cancer risk. Both of those things can be true at once, which is the whole problem.
Emideltide is the one they turned down. It occurs naturally in the brain, it induces sleep, and it acts on the opioid pathway, which raised addiction concerns severe enough to split the room. Credit where it is due, that vote shows the panel was capable of holding a line. It just did not hold many of them.
None of this is binding yet. The FDA has said it will publish a final decision as a proposed rule and open a public comment period first. What the peptide compounding list looks like in twelve months is still being written.
A vote like this opens a door. It does not build the hallway behind it.
Legal to manufacture and good to put in your body are two completely different sentences, and the peptide compounding list only speaks to the first one.
What I have observed across twenty years in sourcing is that the moment something becomes legal to produce, everybody piles in. Some of those operators are excellent. Some are cutting every corner available to them, because there is money on the table and nobody is checking the work. Same compound. Same label. Wildly different vial. You cannot tell the difference by looking, and neither can your doctor.
This is not a peptide problem specifically. It is what happens in any market where demand outruns verification. I have watched it in supplements, I have watched it in biologics, and I have watched clinics on three continents fail to answer basic questions about where their material came from.
One more piece from the reporting that belongs in your thinking. A number of the panelists who voted in favor run clinics that sell peptides. They said openly that they were focused on the patient in front of them rather than on formal approval standards. I understand that impulse. I also think you should know it was in the room when the peptide compounding list expanded.
Most of the peptides under review are injected. That is not a supplement you can stop taking on Tuesday if it disagrees with you.
Now the other end of the same question, and it lands in a very different place.
A team at Keio University in Japan, led by Professor Hideyuki Okano, ran the world’s first clinical study transplanting neural progenitor cells derived from induced pluripotent stem cells into people with spinal cord injuries. iPS cells are ordinary adult cells reprogrammed back to a blank slate. That reprogramming is exactly why the tumor question is the entire ballgame with them.
Between 2020 and 2025 the team transplanted roughly two million of those cells into each of four patients, all treated within four weeks of injury. Last year they reported one-year results. This month they reported the long-term follow-up: two to four years out, no major safety issues, no tumor formation in any of the four, and no clear deterioration in physical function. A formal investigator-initiated trial is planned as early as next year.
Read that timeline again. Years of watching four human beings before anyone would put their name on the word safe.
Japan built a working regulatory pathway for regenerative medicine back in 2014. What a framework like that actually buys is not speed. It is room for serious people to be patient without their work dying in a drawer. That is a very different thing from what the peptide compounding list just did, which was widen access and leave the verifying to whoever feels like doing it.
Four patients is small. That is a real limitation and I am not going to dress it up. But four patients watched carefully for four years tells you something that six compounds waved through in two days cannot.
If you are weighing any of this, the peptide compounding list has effectively handed the burden of proof to you. Here is how to carry it.
I am not a physician and I am not telling you to take or avoid anything. Work with a qualified doctor. What I am telling you is that the peptide compounding list changed who is responsible for asking these questions, and the answer is now you.
There is a line from James Clear’s Atomic Habits that has been following me around for days. It says it does not make sense to keep wanting something if you are not willing to do what it takes to get it, and that if you do not want to live the lifestyle, you should release yourself from the desire. Craving the result but not the process is a guaranteed disappointment.
That line explains this entire week better than any policy analysis could.
The demand behind the peptide compounding list is not irrational. People are hurting, they want options, and they are tired of waiting. I understand that completely. But a great deal of what drives the peptide market is the hope that a compound will deliver an outcome that the person is not otherwise willing to build. That is the crave-the-result problem wearing a lab coat.
The team in Japan is the other posture entirely. Nobody wanted that result more than they wanted to earn it. Four years of process before they would claim anything publicly.
You are allowed to want fewer things. You are not allowed to want them and skip the work.
That applies to your health, your business, and honestly your spiritual life too. If you are not willing to live the process, say so out loud and set the desire down. That is not failure. That is honesty, and it returns an enormous amount of energy you have been quietly spending on something you were never going to chase.
Here is where I land after sitting with both stories.
I am not against access. I refused surgery on my own knee years ago and chose something that had no regulatory blessing at the time, so I am the last person who will tell you to wait politely until an agency gives you a gold star. Access matters. People deserve options.
What I object to is access handed out with nothing attached to it. The peptide compounding list opened a door and then handed you the flashlight, the map, and the liability. If you are going to walk through it anyway, and many of you will, walk through it informed. Ask the six questions. Get the paperwork. Know what is proven and what is promising.
And do the free work first. Every single time.
If you want to know where you actually stand before you start adding compounds to the picture, take the free Base Lift assessment and get an honest baseline. I write about this every week over on Base Lift on Substack, where this week’s full issue covers both of these stories in David’s own words.
Nobody hands you the gate at the top of the mountain. You get the climb, and the climb is where it happens.
7. EF-AQs htmlNo. Being added to the peptide compounding list means compounding pharmacies may prepare a substance without further agency review. It is a permission to manufacture, not a finding of safety or effectiveness, and the recommendations are not binding until the FDA publishes a final rule. Read more →
A Certificate of Analysis is third-party lab confirmation of what a vial contains and at what purity, produced by someone with no financial stake in the result. If a clinic or supplier cannot produce one on request, treat that as your answer. Read more →
Because the risk they were watching for, tumor formation from reprogrammed cells, does not show up in a few months. Following four patients for two to four years is what turns a promising result into one a clinician can act on. Read more →
Ask who made it, ask for the evidence in humans rather than in mice, and ask who profits from your yes. Then ask honestly whether you have done the free work first, because sleep, movement and nutrition still outperform most things you can buy. Read more →
8. Action Step htmlYou do not need a million-dollar program to start working with your biology today. Here is how:
Want the full breakdown? Read the newsletter →
9. Footer CTA html📩 Get David’s weekly insights on longevity, peak performance, and body-mind-spirit alignment. Subscribe to Base Lift on Substack
